30 closest matches · ranked by relevance
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Lung Cancer - Non Small Cell Squamous
Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint — 13.37; 12.42 months — p=0.2517
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Screen Success Rate — 655 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 — 2.63; 1.94 Months — p=0.0103
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 16.7; 8.3 Percentage of Participants
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC V7
Primary: Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA) — 9 percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer (NSCLC)
Primary: Overall Survival (OS) of All Randomized Participants Who Received at Least One Dose of Blinded Study Therapy — NA; NA months
Squamous Cell Carcinoma, Non-Small-Cell Lung
Primary: Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance — 3.12; 2.60 months — p=0.3486
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Lung Cancer
Primary: Overall Survival — 21 months
Lung Cancer
Primary: Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median…